UL Solutions delivered its Q2 results on August 4 and the market's verdict was swift — the stock fell nearly 14% on the day to $78.34, vindicating the defensive positioning that had been building for weeks and now forcing a reassessment of where the trade goes from here.
The short interest story has shifted meaningfully since the pre-earnings notes. Shorts, who had been right to build conviction through June and July, are now trimming. Short interest eased to 7.0% of the free float — around 4.39 million shares — down roughly 5% on the week and pulling back from the 4.9 million share peak hit on July 31. That's a notable reversal of direction. The borrow market remains entirely unstressed: availability is ample at 484%, meaning there are nearly five shares available to lend for every one currently borrowed, and the cost to borrow is just 0.53%. There is no squeeze pressure here. Short sellers are exiting on their own terms, not because the borrow pool is forcing their hand. Options positioning tells a consistent story — the put/call ratio has pulled back to 2.43 from the 2.82 peak of mid-July, easing toward its 20-day mean of 2.02, though it remains well above the sub-1.2 levels that prevailed before the short build began in late June. Protective demand is unwinding, but cautiously.
The Street's reaction to the earnings print was immediate and mostly downward on targets. Citigroup's Arthur Truslove cut his price target sharply — from $106.40 to $82.80 — while holding a Neutral rating, the largest single target reduction in recent months. Wells Fargo's Jason Haas trimmed from $120 to $104, keeping an Overweight. Both moves landed on August 5, the day after the print. The mean analyst target now sits at $98.23, implying roughly 25% upside from the post-earnings close — but that figure reflects targets set before several firms have had a chance to update, so the gap likely narrows as more revisions come through. The consensus remains a hold, with five analysts at that rating and no underperforms on the board. UBS had upgraded to Buy in mid-July at a $110 target; that call is now deeply underwater. Factor scores offer some context on valuation: the EPS surprise rank is near the top of the universe at the 94th percentile, suggesting the company has historically beaten estimates, but the forward earnings momentum rank has slipped to the 4th percentile — the Street is cutting numbers, not raising them.
Insider activity adds a wrinkle worth noting. CEO Jennifer Scanlon sold just over 12,700 shares across multiple tranches on July 1, at prices between $97.92 and $101.74 — a combined value of roughly $1.24 million. The COO sold an additional $2.15 million worth in early June. Neither trade carries a high significance score, and planned selling programs are common at this level. But the timing, with sales completed near the pre-earnings highs before a 20% one-month decline, is the kind of detail that doesn't go unnoticed. The 90-day net insider position across all transactions shows net selling of around $7.7 million.
Institutionally, T. Rowe Price added over two million shares in the most recently reported quarter, and BlackRock added 1.45 million — both meaningful additions that pre-date the earnings drop. Whether those positions get trimmed in the coming quarter will be worth watching in the next 13-F cycle.
The central question now is whether the partial short cover since the print represents conviction that the thesis has played out, or simply profit-taking ahead of further position management. With targets being reset, no next earnings date yet confirmed, and the put/call ratio still running well above its pre-July baseline, the data says caution hasn't fully left the building — just some of it has.
See the live data behind this article on ORTEX.
Open ULS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
